Hodgkin’s lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) are the two most common tumors expressing CD30. Internationally, a clinical study that is being conducted involving adults with recurrent or refractory HL or ALCL suggests efficacy of brentuximab vedotin (SGN-35). Pediatric patients should be given medicines that have been appropriately evaluated for their use. | Phase I clinical study of brentuximab vedotin SGN-35 involving children with recurrent or refractory CD30-positive Hodgkin s lymphoma or systemic anaplastic large cell lymphoma rationale design and methods of BV-HLALCL study Study protocol
